MyMD Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Equity (Tables)

6 Months Ended

Jun. 30, 2014

The expenses related to this private placement are detailed below:

The expenses related to this public offering are as follows:

	$		$
Gross Proceeds:				14,998,500
Underwriter/Aegis Expenses
Underwriter Commission		1,049,895
Underwriter Expenses		149,985
Aegis Legal Fees		80,000
Aegis Registration Expenses		7,500
Aegis Miscellaneous Expenses		36,675
Aegis Road Show Expenses		20,000
Total				1,344,055
Akers Biosciences Expenses
Legal & Accounting Expenses		393,298
Printing & Document Prep		62,101
Registration Expenses		55,946
Road Show Expenses		41,764
Total				553,109
Net Proceeds:				13,101,336